Nykode Therapeutics AS
5VB
Company Profile
Business description
Nykode Therapeutics AS is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immunotherapies. The company is developing individualized cancer neoantigen vaccines and is using the Vaccibody technology to generate therapeutics to treat cancers with a high unmet medical need using it's modular immunotherapy technology, specifically targeting antigens to Antigen Presenting Cells, which are essential for inducing rapid and long-lasting immune responses. It operates in United States of America.
Contact
Gaustadalleen 21
Oslo Research Park
Oslo0349
NORT: +47 22958193
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
59
Stocks News & Analysis
stocks
Do AI labs like Anthropic and OpenAI have economic moats?
Leading AI labs are building economic moats to stave off commodification threats.
stocks
12 picks for an income portfolio - Q3 2026 update
Passive income growth continues to be strong but two picks are facing challenges.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,937.00 | 59.30 | 0.67% |
| CAC 40 | 7,823.78 | 20.45 | 0.26% |
| DAX 40 | 25,208.90 | 121.63 | 0.48% |
| Dow JONES (US) | 51,654.95 | 423.31 | 0.83% |
| FTSE 100 | 10,602.97 | 50.92 | 0.48% |
| HKSE | 24,271.20 | 59.85 | 0.25% |
| NASDAQ | 27,366.17 | 172.83 | 0.64% |
| Nikkei 225 | 69,030.92 | 11.19 | -0.02% |
| NZX 50 Index | 13,827.62 | 78.27 | 0.57% |
| S&P 500 | 7,811.54 | 46.18 | 0.59% |
| S&P/ASX 200 | 8,783.20 | 66.60 | 0.76% |
| SSE Composite Index | 3,797.24 | 16.55 | -0.43% |